path(MESH:"Pick Disease of the Brain")

Entity

Name

Pick Disease of the Brain

Namespace

MeSH

Namespace Version

20181007

Namespace URL

https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns

Mutations in the tau gene can cause the tauopathy Pick’s disease (mentioned above). PubMed:14556719

The band patterns in the immunoblots showed that the AD cases contained a mixture of isoforms, the PiD cases clearly contained 3R isoforms but also some 4R isoforms, while the vast majority of pathology in CBD cases were comprised of 4R tau isoforms PubMed:27574109

The band patterns in the immunoblots showed that the AD cases contained a mixture of isoforms, the PiD cases clearly contained 3R isoforms but also some 4R isoforms, while the vast majority of pathology in CBD cases were comprised of 4R tau isoforms PubMed:27574109

Similarly, the soluble fraction from AD contained the greatest level of TOC1 reactivity, followed by CBD and then PiD had the lowest signal (Fig. 6D; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 16.57, p = 0.001) PubMed:27574109

TOC1 detected significantly more oligomeric tau in AD compared to CBD and PiD and more in CBD compared to PiD (Fig. 6G; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 35.32, p < 0.0001) PubMed:27574109

In contrast, AD soluble tau displayed the highest level of TNT1 followed by CBD, with PiD having the lowest levels (Fig. 6C; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 24.87, p = 0.0002). PubMed:27574109

TNT1 detected significantly more PAD exposed tau in AD compared to PiD, and more in CBD when compared to PiD, but AD and CBD were not different (Fig. 6F; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 12.07, p = 0.0028) PubMed:27574109

Total tau levels in the soluble fractions were similar for AD, CBD and PiD, as indicated by the Tau5 sandwich ELISA (Fig. 6B; one-way ANOVA, F(2,9) = 3.283, p = 0.085) PubMed:27574109

Total tau levels in the insoluble fractions, as detected by Tau5, were highest in AD, followed by CBD and PiD contained the least (Fig. 6E; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 25.93, p = 0.0002) PubMed:27574109

The gross pathological changes consist of brain atrophy, particularly in the hippocampal formation, temporal lobes and parietotemporal cortices, accompanied by cortical thinning, enlarged ventricles and white matter abnormalities, as evident on MRI. PubMed:26195256

Double immunostaining for PICALM and anti-phosphotau antibodies (AT8 and PHF1) showed a co-localisation of PICALM and phosphotau in Pick bodies of Pick disease PubMed:27260836

Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders. PubMed:22057784

Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders. PubMed:22057784

Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders. PubMed:22057784

The band patterns in the immunoblots showed that the AD cases contained a mixture of isoforms, the PiD cases clearly contained 3R isoforms but also some 4R isoforms, while the vast majority of pathology in CBD cases were comprised of 4R tau isoforms PubMed:27574109

The band patterns in the immunoblots showed that the AD cases contained a mixture of isoforms, the PiD cases clearly contained 3R isoforms but also some 4R isoforms, while the vast majority of pathology in CBD cases were comprised of 4R tau isoforms PubMed:27574109

Total tau levels in the soluble fractions were similar for AD, CBD and PiD, as indicated by the Tau5 sandwich ELISA (Fig. 6B; one-way ANOVA, F(2,9) = 3.283, p = 0.085) PubMed:27574109

Total tau levels in the insoluble fractions, as detected by Tau5, were highest in AD, followed by CBD and PiD contained the least (Fig. 6E; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 25.93, p = 0.0002) PubMed:27574109

In contrast, AD soluble tau displayed the highest level of TNT1 followed by CBD, with PiD having the lowest levels (Fig. 6C; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 24.87, p = 0.0002). PubMed:27574109

Similarly, the soluble fraction from AD contained the greatest level of TOC1 reactivity, followed by CBD and then PiD had the lowest signal (Fig. 6D; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 16.57, p = 0.001) PubMed:27574109

TOC1 detected significantly more oligomeric tau in AD compared to CBD and PiD and more in CBD compared to PiD (Fig. 6G; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 35.32, p < 0.0001) PubMed:27574109

TNT1 detected significantly more PAD exposed tau in AD compared to PiD, and more in CBD when compared to PiD, but AD and CBD were not different (Fig. 6F; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 12.07, p = 0.0028) PubMed:27574109

The gross pathological changes consist of brain atrophy, particularly in the hippocampal formation, temporal lobes and parietotemporal cortices, accompanied by cortical thinning, enlarged ventricles and white matter abnormalities, as evident on MRI. PubMed:26195256

Double immunostaining for PICALM and anti-phosphotau antibodies (AT8 and PHF1) showed a co-localisation of PICALM and phosphotau in Pick bodies of Pick disease PubMed:27260836

Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders. PubMed:22057784

Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders. PubMed:22057784

Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders. PubMed:22057784